Raymond James & Associates Compass Pathways PLC Transaction History

Raymond James & Associates

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	SELL	N/A	-19,405 Reduced 60.64%	12,595 $107,000
Q1 2024 Apr 22, 2024	BUY	N/A	4,079 Added 14.61%	32,000 $273,000
Q4 2023 Jan 16, 2024	BUY	N/A	190 Added 0.69%	27,921 $238,000
Q3 2023 Oct 24, 2023	BUY	N/A	27,731 New	27,731 $236,000
Q1 2023 Apr 14, 2023	SELL	$7.32 - $10.85 $43,649 - $64,698	-5,963 Reduced 34.89%	11,128 $110,000
Q4 2022 Feb 08, 2023	SELL	$7.84 - $11.68 $106,796 - $159,104	-13,622 Reduced 44.35%	17,091 $137,000
Q3 2022 Oct 25, 2022	SELL	$10.73 - $20.07 $28,971 - $54,189	-2,700 Reduced 8.08%	30,713 $330,000
Q2 2022 Aug 12, 2022	SELL	$6.76 - $14.18 $6,908 - $14,491	-1,022 Reduced 2.97%	33,413 $362,000
Q1 2022 May 11, 2022	BUY	$11.13 - $23.04 $14,925 - $30,896	1,341 Added 4.05%	34,435 $444,000
Q4 2021 Feb 08, 2022	BUY	$21.81 - $48.96 $721,780 - $1.62 Million	33,094 New	33,094 $731,000
Q3 2021 Nov 02, 2021	SELL	$29.03 - $38.62 $513,221 - $682,762	-17,679 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$32.29 - $39.68 $570,854 - $701,502	17,679 New	17,679 $674,000

151

33.6M

536K

582K

Ticker CMPS
Exchange NASDAQ
Sector Healthcare
Industry Medical Care Facilities
Shares Outstandng 42,522,400
Market Cap $363M
Description
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. Th...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.